|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BROX |
Gene summary for BROX |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BROX | Gene ID | 148362 |
| Gene name | BRO1 domain and CAAX motif containing | |
| Gene Alias | C1orf58 | |
| Cytomap | 1q41 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q5VW32 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 148362 | BROX | P126T-E | Human | Esophagus | ESCC | 1.67e-11 | 9.51e-01 | 0.1125 |
| 148362 | BROX | P127T-E | Human | Esophagus | ESCC | 4.80e-22 | 4.44e-01 | 0.0826 |
| 148362 | BROX | P128T-E | Human | Esophagus | ESCC | 4.00e-19 | 8.43e-01 | 0.1241 |
| 148362 | BROX | P130T-E | Human | Esophagus | ESCC | 2.82e-30 | 7.50e-01 | 0.1676 |
| 148362 | BROX | HCC1_Meng | Human | Liver | HCC | 1.33e-76 | 2.51e-03 | 0.0246 |
| 148362 | BROX | HCC2_Meng | Human | Liver | HCC | 3.14e-44 | 1.95e-01 | 0.0107 |
| 148362 | BROX | cirrhotic2 | Human | Liver | Cirrhotic | 3.17e-11 | 1.65e-01 | 0.0201 |
| 148362 | BROX | HCC1 | Human | Liver | HCC | 5.22e-06 | 4.27e+00 | 0.5336 |
| 148362 | BROX | HCC2 | Human | Liver | HCC | 1.03e-13 | 3.98e+00 | 0.5341 |
| 148362 | BROX | Pt13.b | Human | Liver | HCC | 4.57e-05 | 6.68e-02 | 0.0251 |
| 148362 | BROX | S014 | Human | Liver | HCC | 1.74e-02 | 2.42e-01 | 0.2254 |
| 148362 | BROX | S015 | Human | Liver | HCC | 5.44e-04 | 3.28e-01 | 0.2375 |
| 148362 | BROX | S016 | Human | Liver | HCC | 3.21e-05 | 2.83e-01 | 0.2243 |
| 148362 | BROX | S027 | Human | Liver | HCC | 2.33e-09 | 9.24e-01 | 0.2446 |
| 148362 | BROX | S028 | Human | Liver | HCC | 5.89e-17 | 8.36e-01 | 0.2503 |
| 148362 | BROX | S029 | Human | Liver | HCC | 1.98e-14 | 8.01e-01 | 0.2581 |
| 148362 | BROX | C04 | Human | Oral cavity | OSCC | 9.04e-19 | 1.09e+00 | 0.2633 |
| 148362 | BROX | C21 | Human | Oral cavity | OSCC | 2.83e-48 | 1.27e+00 | 0.2678 |
| 148362 | BROX | C30 | Human | Oral cavity | OSCC | 1.29e-28 | 1.29e+00 | 0.3055 |
| 148362 | BROX | C38 | Human | Oral cavity | OSCC | 1.18e-03 | 7.26e-01 | 0.172 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BROX | SNV | Missense_Mutation | novel | c.108N>C | p.Leu36Phe | p.L36F | Q5VW32 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| BROX | SNV | Missense_Mutation | c.798N>T | p.Lys266Asn | p.K266N | Q5VW32 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD | |
| BROX | SNV | Missense_Mutation | c.1181N>A | p.Pro394His | p.P394H | Q5VW32 | protein_coding | deleterious(0) | benign(0.205) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
| BROX | SNV | Missense_Mutation | novel | c.691N>C | p.Glu231Gln | p.E231Q | Q5VW32 | protein_coding | deleterious(0.03) | benign(0.188) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| BROX | SNV | Missense_Mutation | c.556N>G | p.Gln186Glu | p.Q186E | Q5VW32 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| BROX | SNV | Missense_Mutation | novel | c.961G>C | p.Glu321Gln | p.E321Q | Q5VW32 | protein_coding | tolerated(0.05) | benign(0.015) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| BROX | SNV | Missense_Mutation | c.221C>A | p.Ser74Tyr | p.S74Y | Q5VW32 | protein_coding | deleterious(0.03) | possibly_damaging(0.866) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| BROX | SNV | Missense_Mutation | c.881N>T | p.Thr294Ile | p.T294I | Q5VW32 | protein_coding | tolerated(0.07) | benign(0.145) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| BROX | SNV | Missense_Mutation | novel | c.185N>C | p.Asp62Ala | p.D62A | Q5VW32 | protein_coding | tolerated(0.32) | benign(0.144) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| BROX | SNV | Missense_Mutation | c.221N>A | p.Ser74Tyr | p.S74Y | Q5VW32 | protein_coding | deleterious(0.03) | possibly_damaging(0.866) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |